A multicenter investigation of 2,773 cases of bloodstream infections based on China antimicrobial surveillance network (CHINET).
Humans
Anti-Bacterial Agents
/ pharmacology
Cefepime
Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus
Bacteremia
/ microbiology
Ceftazidime
Cross Infection
/ epidemiology
Anti-Infective Agents
/ pharmacology
Sepsis
/ drug therapy
Staphylococcus
Escherichia coli
China
/ epidemiology
Microbial Sensitivity Tests
Drug Resistance, Bacterial
antimicrobial susceptibility testing
bloodstream infection
community-acquired
hospital-acquired
multicenter investigation
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
10
2022
accepted:
16
11
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
4
1
2023
Statut:
epublish
Résumé
Bloodstream infections (BSIs), especially hospital-acquired BSIs, are a major cause of morbidity and mortality. However, the details about the pathogens and antimicrobial resistance profile of BSIs across China are still lacking. An investigation was conducted in 10 large teaching hospitals from seven geographic regions across China in 2016 based on China Antimicrobial Surveillance Network (CHINET) to profile the clinical and etiological features of BSIs. A total of 2,773 cases of BSIs were identified, a majority (97.3%) of which were monomicrobial. Overall, 38.4% (1,065/2,773) were community-acquired BSIs (CABSIs), and 61.6% (1,708/2,773) were hospital-acquired BSIs (HABSIs). Of the 2,861 pathogenic BSI isolates, 67.5% were Gram-negative bacteria, 29.6% were Gram-positive bacteria, and 2.9% were fungi. The top BSI pathogens were The findings about BSIs in teaching hospitals across China add more scientific evidence to inform the appropriate management of the disease.
Sections du résumé
Background
Bloodstream infections (BSIs), especially hospital-acquired BSIs, are a major cause of morbidity and mortality. However, the details about the pathogens and antimicrobial resistance profile of BSIs across China are still lacking.
Methods
An investigation was conducted in 10 large teaching hospitals from seven geographic regions across China in 2016 based on China Antimicrobial Surveillance Network (CHINET) to profile the clinical and etiological features of BSIs.
Results
A total of 2,773 cases of BSIs were identified, a majority (97.3%) of which were monomicrobial. Overall, 38.4% (1,065/2,773) were community-acquired BSIs (CABSIs), and 61.6% (1,708/2,773) were hospital-acquired BSIs (HABSIs). Of the 2,861 pathogenic BSI isolates, 67.5% were Gram-negative bacteria, 29.6% were Gram-positive bacteria, and 2.9% were fungi. The top BSI pathogens were
Conclusions
The findings about BSIs in teaching hospitals across China add more scientific evidence to inform the appropriate management of the disease.
Identifiants
pubmed: 36590586
doi: 10.3389/fcimb.2022.1075185
pmc: PMC9798236
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cefepime
807PW4VQE3
sultamicillin
65DT0ML581
Ceftazidime
9M416Z9QNR
Anti-Infective Agents
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1075185Informations de copyright
Copyright © 2022 Hu, Yuan, Yang, Xu, Huang, Hu, Ai, Zhuo, Su, Shan, Du, Yu, Lin, Sun, Chen, Xu, Zhang, Wang, He, Ni, Zhang, Lin, Zhu and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor YWT declared a past co-authorship with the authors FH and YY.
Références
Lancet Infect Dis. 2017 Oct;17(10):1042-1052
pubmed: 28818544
Asia Pac J Public Health. 2017 Jul;29(5):451-461
pubmed: 28719790
Infect Drug Resist. 2021 Feb 24;14:731-742
pubmed: 33658810
Int J Clin Pract. 2016 Sep;70(9):706-11
pubmed: 27291693
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S128-S134
pubmed: 30423045
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31010862
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Diagn Microbiol Infect Dis. 2020 Jun;97(2):115016
pubmed: 32111415
Medicine (Baltimore). 2008 Jul;87(4):234-249
pubmed: 18626306
J Antimicrob Chemother. 2016 Dec;71(12):3453-3458
pubmed: 27609052
Antimicrob Resist Infect Control. 2019 Mar 29;8:61
pubmed: 30976388
Front Cell Infect Microbiol. 2020 Jul 03;10:314
pubmed: 32719751
Diagn Microbiol Infect Dis. 2004 Sep;50(1):59-69
pubmed: 15380279
Expert Rev Anti Infect Ther. 2010 Jul;8(7):815-29
pubmed: 20586566
Clin Infect Dis. 2021 Apr 8;72(7):1109-1116
pubmed: 33830222